ReviewCancers2023
Rhabdomyosarcoma: Current Therapy, Challenges, and Future Approaches to Treatment Strategies.
Review in Cancers, 2023. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 60 papers, 1 of them a synthesis that pooled it.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
60 citing papers in PubMed, 1 synthesis or guideline pooled it, 70 citations in OpenAlex.
- A Rare Pediatric Paratesticular Spindle Cell Rhabdomyosarcoma and Systematic Literature Review.Journal of investigative medicine high impact case reportsPooled it
- QSAR modeling and in vitro studies of the selective action of triphenylphosphonium salts as anticancer agents against the rhabdomyosarcoma cell line.Medicinal chemistry research : an international journal for rapid communications on design and mechanisms of action of biologically active agents · 2026Article
- Reannotation of Public Transcriptomic Data Identifies Candidate lncRNAs and Putative Regulatory Networks in Rhabdomyosarcoma.Biomedicines · 2026Article
- Unraveling the dual roles of MICAL2 in skeletal muscle physiology and fusion negative rhabdomyosarcoma tumor progression.Cell death & disease · 2026Article
- Article
- Rhabdomyosarcoma Confined to the Bone Marrow: A Case Report and Literature Review.Current oncology (Toronto, Ont.) · 2026Review
- Nanotechnology-mediated strategies for skeletal muscle repair and regeneration: targeted intervention, functional remodeling, and translational challenges.Journal of nanobiotechnology · 2026Review
- Article
- Article
- Noncoding RNAs in Pediatric Solid Tumors: Advances in Understanding and Critical Knowledge Gaps.Cells · 2026Review
- CAR-T cell immunotherapy in rhabdomyosarcoma.Journal of translational medicine · 2026Review
- Successful Sequential Multimodal Therapy for Lingual Rhabdomyosarcoma in a Young Adult: Case Report.Case reports in oncological medicine · 2026Article
- From bench to bedside: combining HDAC inhibitors with standard therapies in rhabdomyosarcoma treatment.Frontiers in cell and developmental biology · 2026Review
- Pleomorphic rhabdomyosarcoma of the left lower extremity with synchronous gastric and small intestinal metastases presenting as intussusception: a case report.Frontiers in oncology · 2026Article
- TRK immunohistochemistry in pediatric rhabdomyosarcomas: diagnostic and prognostic utility and limitations.Pathology oncology research : POR · 2026Article
- Autophagy andFrontiers in cellular and infection microbiology · 2026Review
- Bifidobacterium enhances the antitumor efficacy of carboplatin in glioblastoma cells: targeting apoptotic and cell cycle regulatory pathways via Caspase, AKT/PTEN, and P53/P21 signaling.Cancer cell international · 2025Article
- Article
- Comprehensive proteome profiling of cytochrome P450 isoforms in cancer models.Clinical proteomics · 2025Article
- Cancer-associated fibroblasts promote tumor progression in fusion-positive rhabdomyosarcoma.Scientific reports · 2025Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
29 authors at 14 institutions in 6 countries.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Rhabdomyosarcoma is a rare cancer arising in skeletal muscle that typically impacts children and young adults. It is a worldwide challenge in child health as treatment outcomes for metastatic and recurrent disease still pose a major concern for both basic and clinical scientists. The treatment strategies for rhabdomyosarcoma include multi-agent chemotherapies after surgical resection with or without ionization radiotherapy. In this comprehensive review, we first provide a detailed clinical understanding of rhabdomyosarcoma including its classification and subtypes, diagnosis, and treatment strategies. Later, we focus on chemotherapy strategies for this childhood sarcoma and discuss the impact of three mechanisms that are involved in the chemotherapy response including apoptosis, macro-autophagy, and the unfolded protein response. Finally, we discuss in vivo mouse and zebrafish models and in vitro three-dimensional bioengineering models of rhabdomyosarcoma to screen future therapeutic approaches and promote muscle regeneration.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.